Product Description
Glutamine is the most abundant and versatile amino acid in the body. Glutamine is the most abundant and versatile amino acid in the body, and is of fundamental importance to intermediary metabolism, interorgan nitrogen exchange via ammonia (NH3) transport between tissues, and pH homeostasis. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266414/)
Mechanisms of Action: GLS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: Orphan Drug - *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Czech | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Korea | Latvia | Lebanon | Lithuania | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Temple Therapeutics
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Gastrointestinal Cancer|Malnutrition|Enteritis|Acute Respiratory Distress Syndrome|Urinary Tract Infections|Urinary Retention|Lyme Disease|Pneumonia|Traumatic Brain Injury|Bone Marrow Transplantation|Hematopoietic Stem Cell Transplant|Anemia, Sickle Cell|Obstetric Labor, Premature|Breast Cancer|Other|Colorectal Cancer|Inflammation|Gastroenteritis|Insulin Resistance|Oxidative Stress|Mucositis|Depressive Disorder|Hypothyroidism|Stomatitis|Type 2 Diabetes|Intestinal Diseases|Cystic Fibrosis
Phase 3: Diarrhea|Kidney Diseases|Peripheral Nervous System Diseases|Vision, Low|Mucositis|Malnutrition|Surgical Wound Infection|Protein Deficiency|Weight Loss|Head and Neck Cancer|Breast Cancer|Esophagitis|Coronary Artery Disease|Breast Diseases|Inflammation|Muscular Dystrophy, Duchenne|COVID-19|Intestinal Diseases|Neck Pain|Other|Sepsis|Colorectal Cancer|Obstetric Labor, Premature|Myocardial Ischemia|Acute Kidney Injury|Heart Failure|Non-Small-Cell Lung Cancer|Respiratory Insufficiency|Pulmonary Valve Insufficiency|Overweight|Burns Unspecified|Oxidative Stress|Cachexia|Hepatitis B|Lung Injury|Weight Gain|Esophageal Cancer|Renal Cell Carcinoma|Carcinogenesis|Eye Cancer|Melanoma|Small Cell Lung Cancer|Obesity|Bone Cancer|Large Cell Carcinoma|Oncology Unspecified|Hepatitis C|Smooth Muscle Tumor|Anemia, Sickle Cell|beta-Thalassemia|Muscle Cancer|Thalassemia|Proctitis|Nose Cancer|Stomatitis|Hepatitis, Animal|Lactose Intolerance|Intestinal Cancer|NUT Carcinoma
Phase 2: Generalized anxiety disorder|Peripheral Nervous System Diseases|Endometriosis|HIV Infections|Acquired Immunodeficiency Syndrome|Other|Coronary Artery Disease|Rheumatic Heart Disease|Multiple Myeloma|Respiratory Aspiration of Gastric Contents|Muscular Dystrophy, Duchenne|Myocardial Ischemia|Mucositis|Stem Cell Transplant|Inflammation|Thalassemia|Transplantation Unspecified|Injuries/wounds Unspecified|Anemia, Sickle Cell|Breast Cancer|Communicable Diseases|Clostridium Infections|Kidney Diseases|Kidney Failure, Chronic|Insulin Resistance|Diarrhea|Colorectal Cancer|Periodontitis|Hyperglycemia|Herpes Labialis|Herpes Simplex|Irritable Bowel Syndrome|Enterocolitis, Pseudomembranous|Healthy Volunteers|Cystic Fibrosis|Kidney Cancer|Prostate Cancer|Hidradenitis Suppurativa|Ileus|Leukemia|Dyspepsia|Sarcoma|Proctitis|Lymphoma|Head and Neck Cancer|Stomatitis|Enteritis|Hypertension, Pulmonary
Phase 1: Breast Cancer|Lymphangioleiomyomatosis|Colonic Diseases|Peripheral Nervous System Diseases|Breast Diseases|Type 2 Diabetes|Crohn Disease|Diverticulosis, Colonic|Traumatic Brain Injury|Propionic Acidemia|Acidosis|Inflammation|Injuries/wounds Unspecified|Colorectal Cancer|Pancreatic Ductal Carcinoma|Head and Neck Cancer|Dermatitis, Atopic|Oncology Solid Tumor Unspecified|Squamous Cell Carcinoma|Generalized anxiety disorder|Adenocarcinoma|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06291038 |
MISSISIIPI | N/A |
Recruiting |
Irritable Bowel Syndrome |
2029-03-01 |
2026-02-21 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
ChiCTR2500108082 |
ChiCTR2500108082 | N/A |
Not yet recruiting |
Colorectal Cancer |
2028-08-19 |
|||
NCT03384108 |
NCT03384108 | N/A |
Recruiting |
Healthy Volunteers |
2028-01-01 |
2026-02-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
ChiCTR2500103114 |
ChiCTR2500103114 | N/A |
Not yet recruiting |
Pancreatic Cancer |
2027-05-20 |
|||
NCT04623502 |
STU-2019-1061 | N/A |
Recruiting |
Transitional Cell Carcinoma|Kidney Cancer|Papillary Adenocarcinoma|Clear Cell Adenocarcinoma|Renal Cell Carcinoma|Papillary Carcinoma|Leiomyomatosis |
2027-04-30 |
2026-01-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT04785989 |
Chronic Lymphocytic Leukemia | N/A |
Recruiting |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2026-10-01 |
2025-10-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT06027242 |
202207099RINA | N/A |
Recruiting |
Gastrointestinal Cancer |
2026-08-30 |
2023-09-09 |
Primary Endpoints|Start Date|Treatments |
|
NCT05972291 |
SPLD-006-22F | N/A |
Recruiting |
Irritable Bowel Syndrome |
2026-07-30 |
2023-10-27 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT04883515 |
OBEGLUT | N/A |
Recruiting |
Obesity|Insulin Resistance |
2026-06-01 |
2026-02-10 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2400082676 |
ChiCTR2400082676 | N/A |
Not yet recruiting |
Heart Failure |
2026-04-02 |
2024-04-03 |
Treatments |
|
NCT06328283 |
Soh-Med-24-02-01MD | N/A |
Not yet recruiting |
Hepatocellular Carcinoma |
2026-03-01 |
2024-03-26 |
Primary Endpoints|Treatments |
|
ChiCTR2500102350 |
ChiCTR2500102350 | N/A |
Recruiting |
Pulmonary Atresia|Pulmonary Heart Disease|Tetralogy of Fallot |
2025-12-31 |
|||
NCT07442084 |
SNS | N/A |
Completed |
Inflammation|Nose Cancer|Vascular Cancer|Inflammatory Breast Cancer|Rectal Diseases|Colorectal Cancer|Gastrointestinal Cancer|Inflammatory Bowel Diseases|Kidney Cancer|Liver Cancer|Breastfeeding|Breast Diseases|Kidney Diseases |
2025-11-01 |
2026-03-03 |
Primary Endpoints |
|
CTR20252983 |
CTR20252983 | N/A |
Completed |
Duodenal Ulcer|Gastritis |
2025-10-16 |
2025-11-09 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT07220447 |
NCI-2025-05686 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified|Generalized anxiety disorder |
2027-07-09 |
2026-02-13 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT03275974 |
NCI-2017-01543 | P1 |
Terminated |
Colorectal Cancer |
2025-12-23 |
2026-01-03 |
Primary Completion Date|Primary Endpoints |
|
2024-516595-15-00 |
HidraQureS/2020 | P2 |
Not yet recruiting |
Hidradenitis Suppurativa |
2027-09-27 |
2025-05-02 |
Treatments |
|
NCT04305769 |
ACT | P2 |
Recruiting |
Enterocolitis, Pseudomembranous|Diarrhea|Clostridium Infections |
2026-12-31 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT07053761 |
NCT07053761 | P2 |
Not yet recruiting |
Proctitis |
2026-06-30 |
2025-07-09 |
Primary Endpoints |
|
NCT07020754 |
FUE.REC25/8-2025 | P2 |
Completed |
Stomatitis|Head and Neck Cancer|Mucositis |
2026-01-01 |
2026-01-31 |
||
NCT05655819 |
NCT05655819 | P2 |
Completed |
Dyspepsia |
2025-12-31 |
2026-02-04 |
Primary Endpoints|Treatments|Trial Status |
|
NCT06617182 |
KY20242229-F-1 | P2 |
Not yet recruiting |
Enteritis |
2025-10-01 |
2024-09-28 |
||
NCT07287592 |
FMASU R 146/2021 | P3 |
Not yet recruiting |
Oncology Unspecified |
2026-12-30 |
2025-12-18 |
Primary Endpoints|Treatments |
|
NCT05852990 |
CEI/1565/21 INCAN/CEI/0074/22 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer|Diarrhea |
2025-12-01 |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT06031012 |
AFMMUChina-oral mucocitis | P3 |
Completed |
Stomatitis|Mucositis |
2025-10-31 |
2026-03-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/05/2026 |
News Article |
Kyowa Hakko's EYEMUSE® Postbiotic Featured in The World's First Postbiotic Eye Gummy |
|
03/03/2026 |
News Article |
Demeetra Publication in Biotechnology Progress Validates Integrated Platforms for Commercial Cell Line Development |
|
02/16/2026 |
News Article |
Drug Reference Apps Market to Reach USD 3.55 Billion by 2035, Driven by Digital Healthcare Adoption and North America's Technological Leadership |
|
12/30/2025 |
News Article |
Emmaus Life Sciences Announces Strategic Transaction |